浙江医药 (600216.SH) Latest Company News

Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:
- finance.sina.cn
Aug 25, 2026, 09:45 UTC
Zhejiang Medicine Co., Ltd. announced its first-half 2026 results, with net profit attributable to shareholders of 606 million yuan, down 9.99% year-on-year.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 24, 2026, 08:42 UTC
Zhejiang Medicine Co., Ltd. announced its first share repurchase of 629,300 shares on August 24, 2026, at prices between 12.55 and 12.83 yuan per share, totaling 7.9997 million yuan, for employee stock ownership plans or equity incentives.
Source:
- finance.sina.cn
Aug 12, 2026, 03:55 UTC
On August 12, 2026, Menova Biopharma's stock price hit the daily limit up at 33.33 yuan per share, with a total market value of 11.33 billion yuan and a peak seal order amount exceeding 1 billion yuan.
Source:
- m.21jingji.com
Aug 11, 2026, 11:08 UTC
Liu Xin became the fourth largest shareholder of Menova (603538.SH) by acquiring 3.9548 million shares, representing 1.63% of total shares, as disclosed in the company's 2026 semi-annual report.
Source:
- finance.sina.cn
Aug 11, 2026, 11:07 UTC
Meinuohua announced its financial results for the first half of 2026, reporting a net profit of 63.6891 million yuan, up 29.83% year-on-year.
Source:
- finance.sina.cn
- m.21jingji.com
Aug 5, 2026, 09:49 UTC
Meinuohua's wholly-owned subsidiary Meinuohua Tiankang was provisionally selected in the 12th national centralized drug procurement for the oral immediate-release formulation of alogliptin, used to treat type 2 diabetes, with a specification of 25mg*30 tablets per bottle.
Source:
- finance.sina.cn
Jul 14, 2026, 08:03 UTC
Zhejiang Medicine plans to repurchase its own shares for 100 million to 200 million yuan at a price not exceeding 17.9 yuan per share.
Source:
- finance.sina.cn
- finance.sina.cn

600216.SH

China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

Zhejiang Medicine Co., Ltd. announced its first-half 2026 results, with net profit attributable to shareholders of 606 million yuan, down 9.99% year-on-year.

Zhejiang Medicine Co., Ltd. announced its first share repurchase of 629,300 shares on August 24, 2026, at prices between 12.55 and 12.83 yuan per share, totaling 7.9997 million yuan, for employee stock ownership plans or equity incentives.

On August 12, 2026, Menova Biopharma's stock price hit the daily limit up at 33.33 yuan per share, with a total market value of 11.33 billion yuan and a peak seal order amount exceeding 1 billion yuan.

Liu Xin became the fourth largest shareholder of Menova (603538.SH) by acquiring 3.9548 million shares, representing 1.63% of total shares, as disclosed in the company's 2026 semi-annual report.

Meinuohua announced its financial results for the first half of 2026, reporting a net profit of 63.6891 million yuan, up 29.83% year-on-year.

Meinuohua's wholly-owned subsidiary Meinuohua Tiankang was provisionally selected in the 12th national centralized drug procurement for the oral immediate-release formulation of alogliptin, used to treat type 2 diabetes, with a specification of 25mg*30 tablets per bottle.

Zhejiang Medicine plans to repurchase its own shares for 100 million to 200 million yuan at a price not exceeding 17.9 yuan per share.